Dose-Escalation and Safety Trial of YN968D1

NCT01497704 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Cancer Patients With Solid Tumors

Interventions

DRUG: YN968D1

Sponsor

Elevar Therapeutics

Collaborators

[object Object]